Lifitegrast
【Chemical Name】Lifitegrast
【Original】Shire
【Time to market】2016.07.11
【Patents expire】2026.05.17
【Dosage and Usage】 Ophthalmic solution, 50 mg/mL (5%).used for the treatment of the signs and
symptoms of dry eye disease
Lifitegrast
一、 Product Overview
Lifitegrast is a drug developed by Shire pharmaceuticals for the treatment of dry eyes. On July 11, 2016, Lifitegrast was approved by the us food and drug administration (FDA) for sale in the us. The patent for the indication expires on May 17, 2026.
二、Main products
Description | Structural Formula | CAS No. | Category |
Lifitegrast |
| 1025967-78-5 | API |
(S)-methyl 2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride |
| 851785-21-2 | intermediates |
(S)-benzyl 2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride |
| 1194550-59-8 | intermediates |
2-(tert-butoxycarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid |
| 851784-82-2 | intermediates |
Isoquinolinecarboxylic acid, 5,7-dichloro-1,2,3,4-tetrahydro-, hydrochloride |
| 1289646-93-0 | intermediates |
(S)-2-amino-3-(3-(methylsulfonyl)phenyl) propanoic acid hydrochloride |
| 2177264-60-5 | intermediates |
Benzofuran-6-carboxylic acid |
| 77095-51-3 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.